Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Journal: Current oncology reports
Published: May 04, 2016
Toremifene for breast cancer: a review of 20 years of data.
Journal: Clinical breast cancer
Published: June 05, 2013
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
Journal: The Lancet. Oncology
Published: March 19, 2013
Showing 1-4 of 4
Last Updated: 09/26/2026